ThromboGenics NV announced it has strengthened its senior leadership team with the appointment of Susan Schneider, MD, as Chief Medical Officer, and Vinciane Vangeersdaele as Chief Commercial Officer. Both will be members of the company's executive team reporting to ThromboGenics' CEO, and they will operate from the Company's offices in Leuven, Belgium and Iselin, New Jersey, US. Susan Schneider, MD, brings nearly 15 years of experience in clinical drug development to ThromboGenics. Prior to joining ThromboGenics, she was, most recently, Vice President & Therapeutic Area Head of Retina & Glaucoma at Allergan. Susan received her medical degree from the Medical College of Pennsylvania followed by a residency in ophthalmology at the Medical College of Virginia. At ThromboGenics, Dr. Schneider will be responsible for the development and execution of the Company's global clinical and medical programs that are focused on its pipeline of drug candidates targeting diabetic eye disease.